SEC Form 4 · accession 0000904454-17-000097
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Bigham
Officer — Chairman and CEO · Director
Period of report
Feb 2, 2017
Accepted (ET)
Feb 6, 2017 · 7:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $15.10 | Feb 2, 2017 | A | 72,500 | A | — | Feb 1, 2027 | Common Stock | 72,500 | 72,500 | D |
Explanation of responses
- F1The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant.
- F2The shares shall vest as to 1/36 of the shares on the one-month anniversary following February 2, 2017 and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date.